Use of a continuous culture fermentation system to investigate the effect of GanedenBC30 (Bacillus coagulans GBI-30, 6086) supplementation on pathogen survival in the human gut microbiota.
- 2011-02
- Anaerobe 17(1)
- H. Honda
- G. Gibson
- S. Farmer
- D. Keller
- A. McCartney
- PubMed: 21195203
- DOI: 10.1016/j.anaerobe.2010.12.006
Abstract
Single-stage continuous fermentation systems were employed to examine the effects of GanedenBC(30) supplementation on the human gastrointestinal microbiota in relation to pathogen challenge in vitro. Denaturing gradient gel electrophoresis analysis demonstrated that GanedenBC(30) supplementation modified the microbial profiles in the fermentation systems compared with controls, with profiles clustering according to treatment. Overall, GanedenBC(30) supplementation did not elicit major changes in bacterial population counts in vitro, although notably higher Bcoa191 counts were seen following probiotic supplementation (compared to the controls). Pathogen challenge did not elicit significant modification of the microbial counts in vitro, although notably higher Clit135 counts were seen in the control system post-Clostridium difficile challenge than in the corresponding GanedenBC(30)-supplemented systems. Sporulation appears to be associated with the anti-microbial activity of GanedenBC(30), suggesting that a bi-modal lifecycle of GanedenBC(30)in vivo may lead to anti-microbial activity in distal regions of the gastrointestinal tract.
Research Insights
Supplement | Health Outcome | Effect Type | Effect Size |
---|---|---|---|
Bacillus coagulans GBI-30, 6086 | Altered Microbial Profile | Neutral | Small |
Bacillus coagulans GBI-30, 6086 | Decreased Clit135 Counts | Beneficial | Small |
Bacillus coagulans GBI-30, 6086 | Enhanced Antimicrobial Activity | Beneficial | Moderate |
Bacillus coagulans GBI-30, 6086 | Increased Bcoa191 Counts | Neutral | Small |